Drug product development and case studies for patient centric pediatric protein-based therapeutics

IF 3.7 3区 医学 Q2 CHEMISTRY, MEDICINAL
Annette Medina , Mary N. Brown , Emily Cox , Sarah Donegan , Sonia Dragulin-Otto , Katiria Flores , Nathalie Fuentes , Lisa Glasser , Stanley C. Kwok , Ian Lent , Angeliki Siapkara , Yujing Wang
{"title":"Drug product development and case studies for patient centric pediatric protein-based therapeutics","authors":"Annette Medina ,&nbsp;Mary N. Brown ,&nbsp;Emily Cox ,&nbsp;Sarah Donegan ,&nbsp;Sonia Dragulin-Otto ,&nbsp;Katiria Flores ,&nbsp;Nathalie Fuentes ,&nbsp;Lisa Glasser ,&nbsp;Stanley C. Kwok ,&nbsp;Ian Lent ,&nbsp;Angeliki Siapkara ,&nbsp;Yujing Wang","doi":"10.1016/j.xphs.2024.07.014","DOIUrl":null,"url":null,"abstract":"<div><div>The user of a pediatric drug includes not only the patient, but also their caregiver and healthcare provider, including nurses, doctors, and pharmacists. Therefore, adopting a patient-centric approach that focuses on all users is critical for the development of pediatric drug products. This article outlines the quality target product profile parameters and a patient-centric approach for the development of pediatric protein-based therapies. The use environment, formulation design, and preparation and in use stability considerations are described. An acceptability profile for the various routes of parenteral administration is described with a focus on pediatric age groups. Furthermore, a risk assessment approach is presented for the selection of excipients to be utilized in pediatric protein-based biopharmaceuticals. Several case studies are included which illustrate the selection of drug product parameters such as formulation, dose volume, and route of administration with the pediatric user in mind.</div></div>","PeriodicalId":16741,"journal":{"name":"Journal of pharmaceutical sciences","volume":"114 2","pages":"Pages 681-689"},"PeriodicalIF":3.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022354924002600","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

The user of a pediatric drug includes not only the patient, but also their caregiver and healthcare provider, including nurses, doctors, and pharmacists. Therefore, adopting a patient-centric approach that focuses on all users is critical for the development of pediatric drug products. This article outlines the quality target product profile parameters and a patient-centric approach for the development of pediatric protein-based therapies. The use environment, formulation design, and preparation and in use stability considerations are described. An acceptability profile for the various routes of parenteral administration is described with a focus on pediatric age groups. Furthermore, a risk assessment approach is presented for the selection of excipients to be utilized in pediatric protein-based biopharmaceuticals. Several case studies are included which illustrate the selection of drug product parameters such as formulation, dose volume, and route of administration with the pediatric user in mind.
以用户为中心的儿科蛋白质治疗药物产品开发和案例研究。
儿科药物的使用者不仅包括患者,还包括他们的护理人员和医疗服务提供者,包括护士、医生和药剂师。因此,采用以患者为中心、关注所有用户的方法对于儿科药物产品的开发至关重要。本文概述了开发儿科蛋白质疗法的优质目标产品特征参数和以患者为中心的方法。文章介绍了使用环境、制剂设计、制备和使用中稳定性方面的注意事项。介绍了各种肠外给药途径的可接受性概况,重点是儿科年龄组。此外,还介绍了儿科蛋白质生物制药辅料选择的风险评估方法。其中还包括几个案例研究,说明在选择药物产品参数(如配方、剂量和给药途径)时应考虑到儿科用户。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.30
自引率
13.20%
发文量
367
审稿时长
33 days
期刊介绍: The Journal of Pharmaceutical Sciences will publish original research papers, original research notes, invited topical reviews (including Minireviews), and editorial commentary and news. The area of focus shall be concepts in basic pharmaceutical science and such topics as chemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability of drugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信